Cargando…

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations

BACKGROUND: Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in PIK3CA gene predict worse response to neoadjuvant chemotherapy for HER2-positive patients, while their role is less clearly defined for HER2-negative tumors....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocciolone, Valentina, Cannita, Katia, Tessitore, Alessandra, Mastroiaco, Valentina, Rinaldi, Lucia, Paradisi, Stefania, Irelli, Azzurra, Baldi, Paola Lanfiuti, Sidoni, Tina, Ricevuto, Enrico, Dal Mas, Antonella, Calvisi, Giuseppe, Coletti, Gino, Ciccozzi, Antonietta, Pizzorno, Laura, Resta, Valter, Bafile, Alberto, Alesse, Edoardo, Ficorella, Corrado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007957/ https://www.ncbi.nlm.nih.gov/pubmed/29937992 http://dx.doi.org/10.18632/oncotarget.25270

Ejemplares similares

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis
por: Cocciolone, Valentina, et al.
Publicado: (2017)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
por: Irelli, Azzurra, et al.
Publicado: (2022)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2018)

Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
por: Irelli, Azzurra, et al.
Publicado: (2023)

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes
por: Zelli, Veronica, et al.
Publicado: (2020)

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity
por: Cianci, G, et al.
Publicado: (2003)

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
por: Bruera, Gemma, et al.
Publicado: (2010)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
por: Ficorella, C, et al.
Publicado: (2004)

Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model
por: Del Vecchio, Filippo, et al.
Publicado: (2015)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Next-generation sequencing: recent applications to the analysis of colorectal cancer
por: Del Vecchio, Filippo, et al.
Publicado: (2017)

Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model
por: Tessitore, Alessandra, et al.
Publicado: (2017)

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
por: Bruera, Gemma, et al.
Publicado: (2014)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice
por: Tessitore, Alessandra, et al.
Publicado: (2016)

Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception
por: Irelli, Azzurra, et al.
Publicado: (2022)

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling
por: Di Benedetto, Paola, et al.
Publicado: (2019)

Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer
por: Zelli, Veronica, et al.
Publicado: (2020)

Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay
por: Zollino, Marcella, et al.
Publicado: (2019)

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
por: Cortellini, Alessio, et al.
Publicado: (2020)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015)

Microwave-Assisted Vacuum Synthesis of TiO(2) Nanocrystalline Powders in One-Pot, One-Step Procedure
por: Paradisi, Enrico, et al.
Publicado: (2021)

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy
por: Cortellini, Alessio, et al.
Publicado: (2017)

Sex and Gender Influences on Cancer Immunotherapy Response
por: Irelli, Azzurra, et al.
Publicado: (2020)

Emotional “Patient-Oriented” Support in Young Patients With I–II Stage Breast Cancer: Pilot Study
por: Di Giacomo, D., et al.
Publicado: (2018)

What Is Known about Theragnostic Strategies in Colorectal Cancer
por: Parisi, Alessandro, et al.
Publicado: (2021)

Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients
por: Romano, S, et al.
Publicado: (2011)

Neuroendocrine Cancer of the Breast: A Rare Entity
por: Irelli, Azzurra, et al.
Publicado: (2020)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h2721pjpphqe6fqs089ipjoav6